Skip to main content
. 2019 Mar 1;10(4):584–597. doi: 10.1039/c8md00620b

Table 2. Cytotoxicity of compounds 5a–5h and 6a–6l against different cancer cell lines.

Compd. IC50 a (μM)
RF c
T24 HepG2 A549 NCI-H460 NCI-H460/DOX HL-7702
5a 27.39 ± 1.15 29.76 ± 0.57 26.71 ± 1.06 26.84 ± 0.36 n.d. b >50
5b 33.82 ± 0.63 37.55 ± 0.88 33.47 ± 1.21 34.63 ± 0.99 n.d. >50
5c 20.27 ± 0.54 25.12 ± 1.25 18.51 ± 1.34 20.78 ± 0.85 >50 >50
5d 39.28 ± 1.26 43.75 ± 1.48 38.23 ± 1.26 40.91 ± 1.37 n.d. >50
5e >50 >50 >50 >50 n.d. >50
5f 22.47 ± 1.23 26.93 ± 0.91 21.85 ± 0.68 23.50 ± 0.59 n.d. >50
5g 17.33 ± 1.09 21.48 ± 0.78 16.74 ± 0.93 19.06 ± 0.76 27.11 ± 1.05 >50 1.42
5h 31.95 ± 0.43 36.84 ± 0.96 30.26 ± 0.87 34.49 ± 1.14 n.d. >50
6a 23.62 ± 1.35 28.42 ± 1.03 20.36 ± 0.62 24.96 ± 1.46 n.d. >50
6b 34.49 ± 1.12 37.29 ± 1.07 33.15 ± 0.98 34.88 ± 0.75 n.d. >50
6c 9.10 ± 0.74 10.32 ± 0.45 8.98 ± 0.56 9.65 ± 0.29 14.43 ± 0.58 >50 1.49
6d >50 >50 >50 >50 n.d. >50
6e 37.69 ± 0.71 40.58 ± 0.87 35.68 ± 1.25 39.73 ± 0.79 n.d. >50
6f 41.14 ± 2.58 45.80 ± 1.80 39.87 ± 1.55 43.57 ± 1.64 n.d. >50
6g 14.95 ± 1.15 18.71 ± 0.90 14.78 ± 0.32 15.92 ± 0.57 17.41 ± 0.34 >50 1.09
6h >50 >50 >50 >50 n.d. >50
6i 9.61 ± 0.63 12.66 ± 0.86 9.24 ± 1.14 11.74 ± 0.37 13.99 ± 0.95 >50 1.19
6j 10.67 ± 0.72 14.87 ± 0.37 10.20 ± 0.49 12.05 ± 0.84 16.92 ± 1.01 >50 1.40
6k 3.96 ± 0.21 5.24 ± 1.34 2.67 ± 0.06 4.46 ± 0.15 4.84 ± 0.42 >50 1.08
6l 7.51 ± 0.54 8.36 ± 1.11 5.16 ± 0.51 7.85 ± 0.83 10.27 ± 0.35 >50 1.31
AA 43.97 ± 1.36 35.37 ± 1.47 41.02 ± 0.78 44.82 ± 1.25 n.d. >50
DOX 0.96 ± 0.09 1.37 ± 0.24 1.07 ± 0.18 0.8 ± 0.06 30.99 ± 1.15 10.44 ± 0.5 38.74

aIC50 values are presented as the mean ± SD (standard error of the mean) from three separate experiments.

bn.d. = not detected.

cRF (resistant factor) is defined as IC50 in NCI-H460/DOX/IC50 in NCI-H460.